RBBP8 and triple-negative breast carcinoma: Because patients diagnosed with triple negative breast cancer (TNBC) have a higher risk of disease relapse within 5 years than patients treated for other breast cancer subtypes [22], we compared the CtIP mRNA level in TNBC to that in non-TNBC by using one publicly available microarray dataset (GSE47561 [23]).